SI0998556T1 - Diagnosis and treatment of diseases using anti-t-cell receptor vbeta antibodies or peptides which are recognized by said antibodies, and endocrine secretion regulatory protein 1 (esrp1) - Google Patents
Diagnosis and treatment of diseases using anti-t-cell receptor vbeta antibodies or peptides which are recognized by said antibodies, and endocrine secretion regulatory protein 1 (esrp1)Info
- Publication number
- SI0998556T1 SI0998556T1 SI9830782T SI9830782T SI0998556T1 SI 0998556 T1 SI0998556 T1 SI 0998556T1 SI 9830782 T SI9830782 T SI 9830782T SI 9830782 T SI9830782 T SI 9830782T SI 0998556 T1 SI0998556 T1 SI 0998556T1
- Authority
- SI
- Slovenia
- Prior art keywords
- antibodies
- diseases
- esrp1
- peptides
- diagnosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9715281A GB2327423B (en) | 1997-07-21 | 1997-07-21 | Ligands, including antibodies, showing reactivity against endocrine cells for use in therapy and diagnosis |
GBGB9810676.8A GB9810676D0 (en) | 1998-05-18 | 1998-05-18 | Ligands including antibodies showing reactivity against endocrine cells for use in therapy and diagnosis |
EP98935160A EP0998556B1 (de) | 1997-07-21 | 1998-07-20 | Diagnose und behandlung von krankheiten mittels anti-t-zell rezeptor-vbeta-antikörper oder peptide, an denen diese antikörper spezifisch binden, und esrp1 |
PCT/GB1998/002151 WO1999005175A2 (en) | 1997-07-21 | 1998-07-20 | Diagnosis and treatment of diseases using anti-anti-t-cell receptor vbeta anti-bodies or peptides which are recognized by said antibodies, and endocrine secretion regulatory protein i (esrp1) |
Publications (1)
Publication Number | Publication Date |
---|---|
SI0998556T1 true SI0998556T1 (en) | 2005-10-31 |
Family
ID=26311906
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI9830782T SI0998556T1 (en) | 1997-07-21 | 1998-07-20 | Diagnosis and treatment of diseases using anti-t-cell receptor vbeta antibodies or peptides which are recognized by said antibodies, and endocrine secretion regulatory protein 1 (esrp1) |
Country Status (21)
Country | Link |
---|---|
US (2) | US6689359B1 (de) |
EP (2) | EP1595951A1 (de) |
JP (1) | JP2002511765A (de) |
KR (2) | KR100567277B1 (de) |
CN (1) | CN1330754C (de) |
AT (1) | ATE297983T1 (de) |
AU (1) | AU758455B2 (de) |
BR (1) | BR9810118A (de) |
CA (1) | CA2296842C (de) |
CU (1) | CU23412A3 (de) |
DE (1) | DE69830588T2 (de) |
DK (1) | DK0998556T3 (de) |
EA (1) | EA003131B1 (de) |
ES (1) | ES2245034T3 (de) |
IL (3) | IL133277A0 (de) |
NZ (1) | NZ501424A (de) |
PL (1) | PL204503B1 (de) |
PT (1) | PT998556E (de) |
SI (1) | SI0998556T1 (de) |
TR (1) | TR200000181T2 (de) |
WO (1) | WO1999005175A2 (de) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1366901A (en) * | 1999-09-23 | 2001-04-24 | Rigel Pharmaceuticals, Inc. | Traf4 associated cell cycle proteins, compositions and methods of use |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
AU2012241141B2 (en) * | 2005-08-11 | 2015-08-20 | Arpi Matossian-Rogers | TCR-V-beta related peptides for treatment and diagnosis of autoimmune disease |
GB2429013C (en) | 2005-08-11 | 2012-11-28 | Arpi Matossian-Rogers | Peptides for treatment and diagnosis of autoimmunedisease |
PL2289909T3 (pl) | 2005-11-30 | 2015-04-30 | Abbvie Inc | Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał |
CN102898519B (zh) | 2005-11-30 | 2015-10-28 | Abbvie公司 | 抗淀粉样β蛋白的单克隆抗体及其用途 |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
WO2009048539A2 (en) | 2007-10-05 | 2009-04-16 | Genentech, Inc. | Monoclonal antibody |
EP2558494B1 (de) | 2010-04-15 | 2018-05-23 | AbbVie Inc. | Amyloid-beta-bindende proteine |
NZ606357A (en) | 2010-07-30 | 2015-05-29 | Genentech Inc | Safe and functional humanized anti beta-amyloid antibody |
US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
SI2761065T1 (en) * | 2011-09-29 | 2018-02-28 | Cellsnap, Llc | Ingredients and procedures for toxicity testing |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2072356A1 (en) | 1989-12-29 | 1991-06-30 | James L. Urban | Diagnosis and treatment of diseases |
US5216132A (en) * | 1990-01-12 | 1993-06-01 | Protein Design Labs, Inc. | Soluble t-cell antigen receptor chimeric antigens |
JPH06507384A (ja) | 1991-01-22 | 1994-08-25 | ザ イミューン レスポンス コーポレイション | 特定のt細胞群による病理的応答により生じる疾患に対するワクチン投与および方法 |
US5480895A (en) * | 1991-09-27 | 1996-01-02 | New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery | Method of producing antibodies to a restricted population of T lymphocytes, antibodies produced therefrom and methods of use thereof |
US5891623A (en) * | 1992-11-09 | 1999-04-06 | Consorzio Per Le Biotecnologie | Diagnosis and treatment of AIDS onset |
US5595721A (en) * | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
US5589328A (en) * | 1994-08-04 | 1996-12-31 | Mahant; Vijay K. | Chemiluminescence assays based on indoxyl substrates, thioindoxyl substrates and other substrates |
-
1998
- 1998-07-20 KR KR1020007000632A patent/KR100567277B1/ko not_active IP Right Cessation
- 1998-07-20 TR TR2000/00181T patent/TR200000181T2/xx unknown
- 1998-07-20 JP JP50949099A patent/JP2002511765A/ja not_active Ceased
- 1998-07-20 AU AU84517/98A patent/AU758455B2/en not_active Ceased
- 1998-07-20 EA EA200000146A patent/EA003131B1/ru not_active IP Right Cessation
- 1998-07-20 SI SI9830782T patent/SI0998556T1/xx unknown
- 1998-07-20 US US09/463,158 patent/US6689359B1/en not_active Expired - Fee Related
- 1998-07-20 NZ NZ501424A patent/NZ501424A/en not_active IP Right Cessation
- 1998-07-20 DE DE69830588T patent/DE69830588T2/de not_active Expired - Lifetime
- 1998-07-20 PL PL338449A patent/PL204503B1/pl not_active IP Right Cessation
- 1998-07-20 PT PT98935160T patent/PT998556E/pt unknown
- 1998-07-20 EP EP05076378A patent/EP1595951A1/de not_active Withdrawn
- 1998-07-20 KR KR1020057007380A patent/KR100670070B1/ko not_active IP Right Cessation
- 1998-07-20 CA CA2296842A patent/CA2296842C/en not_active Expired - Fee Related
- 1998-07-20 EP EP98935160A patent/EP0998556B1/de not_active Expired - Lifetime
- 1998-07-20 CN CNB988073803A patent/CN1330754C/zh not_active Expired - Fee Related
- 1998-07-20 ES ES98935160T patent/ES2245034T3/es not_active Expired - Lifetime
- 1998-07-20 DK DK98935160T patent/DK0998556T3/da active
- 1998-07-20 IL IL13327798A patent/IL133277A0/xx active IP Right Grant
- 1998-07-20 AT AT98935160T patent/ATE297983T1/de active
- 1998-07-20 BR BR9810118-8A patent/BR9810118A/pt not_active Application Discontinuation
- 1998-07-20 WO PCT/GB1998/002151 patent/WO1999005175A2/en active IP Right Grant
-
1999
- 1999-12-02 IL IL133277A patent/IL133277A/en not_active IP Right Cessation
-
2000
- 2000-01-18 CU CU20000009A patent/CU23412A3/es not_active IP Right Cessation
-
2003
- 2003-10-01 US US10/674,433 patent/US20050100541A1/en not_active Abandoned
-
2006
- 2006-05-31 IL IL176076A patent/IL176076A/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL176076A0 (en) | Ligands,including antibodies showing, reactivity against endocrine cells | |
HK1021025A1 (en) | Process for in vitro detecting the presence or absence of antibodies to anti-tissue transglutinase from body fluids. | |
ATE283289T1 (de) | Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten | |
KR910002897A (ko) | 에리트로포이에틴(epo)펩타이드 및 이에 대한 항체 | |
BR0112602A (pt) | Compostos e métodos para tratamento e diagnóstico de infecção clamidial | |
MX9801687A (es) | Compuestos y metodos para el diagnostico de tuberculosis. | |
IE890853L (en) | Monoclonal Antibodies | |
ATE421531T1 (de) | Apoptose-bezogene verbindungen und deren verwendung | |
WO1996021734A3 (en) | P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods | |
CA2344590A1 (en) | Treatment of inflammatory disease | |
DK0687180T3 (da) | Fremgangsmåde til påvisning og behandling af individer, som har unormale celler, som udtrykker HLC-A2/tyrosinasepeptid-anti | |
WO2001096372A3 (en) | Zinc transporters proteins and their use in medicinal preparations | |
NO962596L (no) | Nytt tumorsupressorgen | |
WO2002088378A3 (en) | 66784, a novel human potassium channel and uses therefor | |
FI950962A (fi) | Menetelmä anti-DNA-vasta-aineiden toteamiseksi, diagnostinen menetelmä, reagenssipakkaus ja lääkeaine autoimmuunisairauksia varten | |
WO1999051725A3 (en) | Assay for the diagnosis of schizophrenia based on a new peptide | |
CA2140091A1 (en) | Peptides and antisera for detecting human cyclooxygenase-1 and cyclooxygenase-2 | |
WO1998041538A3 (en) | Novel human cytokine/steroid receptor protein | |
WO2002026958A3 (en) | Human neprilysin protease | |
NO941458L (de) | ||
AU2003215667A1 (en) | Diagnostic and therapeutic use of human maguin proteins and nucleic acids for neurodegenerative diseases | |
WO2001066746A3 (en) | G-protein coupled receptor related polypeptides |